文献速递临床试验与 GCP基础与转化研究

结核候选疫苗MVA85A交替气溶胶与全身免疫接种的I期随机对照试验

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
PubMed 文献 · PLoS Med · 2019-04-30

该I期随机对照试验于2013年12月至2016年1月在英国纳入36名已接种卡介苗的健康成人,均分3组比较气溶胶-皮内、皮内-气溶胶与皮内-皮内两种MVA85A接种方案。气溶胶初免耐受良好且免疫原性强;皮内初免后气溶胶加强引起短暂中重度呼吸道和全身不良事件,仅该组对Ag85A细胞免疫有适度显著增强(p=0.027;95%CI:28至630个斑点形成细胞/1×10^6外周血单个核细胞)。

要点

  • 36名已接种卡介苗的健康成人随机均分3组,间隔1个月接种2剂MVA85A。
  • 气溶胶初免耐受良好,呼吸道不良事件均为轻度,无严重不良事件。
  • 皮内初免-气溶胶加强组出现短暂中重度呼吸道和全身不良事件。

核心结论

  • 气溶胶初免-皮内加强方案耐受良好,气溶胶接种可诱导强效Ag85A特异性黏膜和全身细胞免疫。
  • 皮内初免-气溶胶加强引起短暂但显著的呼吸道不良事件。
  • 诱导强效黏膜和全身免疫对保护力的意义尚不明确。

研究设计与样本

  • I期随机对照试验,2013年12月至2016年1月在英国纳入36名已接种卡介苗的健康成人,随机均分3组。
  • 各组间隔1个月接种2剂MVA85A:第1组气溶胶-皮内,第2组皮内-气溶胶,第3组皮内-皮内。
  • 接种后7天行支气管镜和支气管肺泡灌洗,不良事件和外周血采集至接种后6个月。
  • 实验室和支气管镜团队对分组设盲;1名参与者退出并被替换;参与者年龄21-42岁,28/37为女性。
  • 临床试验注册号:ClinicalTrials.gov NCT01954563。

主要发现

  • 气溶胶初免耐受良好且免疫原性强,不良事件多为皮内接种后轻度局部注射部位反应。
  • 两种途径接种后均出现短暂全身不良事件,多为轻度;第1组气溶胶初免后所有呼吸道不良事件均为轻度。
  • 第2组皮内初免后气溶胶加强引起短暂中重度呼吸道和全身不良事件。
  • 无严重不良事件,无支气管镜相关并发症。
  • 仅第2组对Ag85A细胞免疫有适度显著增强(p=0.027;95%CI:28至630个斑点形成细胞/1×10^6外周血单个核细胞)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 第2组因不良事件特征未对该组最后3名参与者进行加强接种。
  • 支气管镜时间安排旨在捕捉黏膜应答峰值,但峰值应答可能出现在该时间窗之外。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is an urgent need for an effective tuberculosis (TB) vaccine. Heterologous prime-boost regimens induce potent cellular immunity. MVA85A is a candidate TB vaccine. This phase I clinical trial was designed to evaluate whether alternating aerosol and intradermal vaccination routes would boost cellular immunity to the Mycobacterium tuberculosis antigen 85A (Ag85A). METHODS AND FINDINGS: Between December 2013 and January 2016, 36 bacille Calmette-Guérin-vaccinated, healthy UK adults were randomised equally between 3 groups to receive 2 MVA85A vaccinations 1 month apart using either heterologous (Group 1, aerosol-intradermal; Group 2, intradermal-aerosol) or homologous (Group 3, intradermal-intradermal) immunisation. Bronchoscopy and bronchoalveolar lavage (BAL) were performed 7 days post-vaccination. Adverse events (AEs) and peripheral blood were collected for 6 months post-vaccination. The laboratory and bronchoscopy teams were blinded to treatment allocation. One participant was withdrawn and was replaced. Participants were aged 21-42 years, and 28/37 were female. In a per protocol analysis, aerosol delivery of MVA85A as a priming immunisation was well tolerated and highly immunogenic. Most AEs were mild local injection site reactions following intradermal vaccination. Transient systemic AEs occurred following vaccination by both routes and were most frequently mild. All respiratory AEs following primary aerosol MVA85A (Group 1) were mild. Boosting an intradermal MVA85A prime with an aerosolised MVA85A boost 1 month later (Group 2) resulted in transient moderate/severe respiratory and systemic AEs. There were no serious adverse events and no bronchoscopy-related complications. Only the intradermal-aerosol vaccination regimen (Group 2) resulted in modest, significant boosting of the cell-mediated immune response to Ag85A (p = 0.027; 95% CI: 28 to 630 spot forming cells per 1 × 106 peripheral blood mononuclear cells). All 3 regimens induced systemic cellular immune responses to the modified vaccinia virus Ankara (MVA) vector. Serum antibodies to Ag85A and MVA were only induced after intradermal vaccination. Aerosolised MVA85A induced significantly higher levels of Ag85A lung mucosal CD4+ and CD8+ T cell cytokines compared to intradermal vaccination. Boosting with aerosol-inhaled MVA85A enhanced the intradermal primed responses in Group 2. The magnitude of BAL MVA-specific CD4+ T cell responses was lower than the Ag85A-specific responses. A limitation of the study is that while the intradermal-aerosol regimen induced the most potent cellular Ag85A immune responses, we did not boost the last 3 participants in this group because of the AE profile. Timing of bronchoscopies aimed to capture peak mucosal response; however, peak responses may have occurred outside of this time frame. CONCLUSIONS: To our knowledge, this is the first human randomised clinical trial to explore heterologous prime-boost regimes using aerosol and systemic routes of administration of a virally vectored vaccine. In this trial, the aerosol prime-intradermal boost regime was well tolerated, but intradermal prime-aerosol boost resulted in transient but significant respiratory AEs. Aerosol vaccination induced potent cellular Ag85A-specific mucosal and systemic immune responses. Whilst the implications of inducing potent mucosal and systemic immunity for protection are unclear, these findings are of relevance for the development of aerosolised vaccines for TB and other respiratory and mucosal pathogens. TRIAL REGISTRATION: ClinicalTrials.gov NCT01954563.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Manjaly Thomas ZR, Satti I, Marshall JL, et al. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial. PLoS Med. 2019. PMID: 31039172. doi:10.1371/journal.pmed.1002790

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。